
Jan 12 (Reuters) - RemeGen Co Ltd 688331.SS:
ABBVIE AND REMEGEN ANNOUNCE EXCLUSIVE LICENSING AGREEMENT TO DEVELOP A NOVEL BISPECIFIC ANTIBODY FOR ADVANCED SOLID TUMORS
ABBVIE: REMEGEN ELIGIBLE TO RECEIVE UP TO USD $4.95 BILLION IN AGGREGATE DEVELOPMENT, REGULATORY, AND COMMERCIAL MILESTONE PAYMENTS
ABBVIE: REMEGEN WILL RECEIVE AN UPFRONT PAYMENT OF UPTO $650 MILLION
ABBVIE: WILL RECEIVE EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE, AND COMMERCIALIZE RC148 OUTSIDE OF GREATER CHINA TERRITORY
ABBVIE: REMEGEN WILL RECEIVE AN UPFRONT PAYMENT OF USD $650 MILLION